Skip to main content

Advertisement

Table 5 Predictors of drug-attributable falls in haematocrit (DAFH) in excess of 4% in <5 year-old children with uncomplicated falciparum malaria following artemisinin-based combination treatments

From: Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials

Variable Total no. No. with DAFH >4% OR (95% CI) P value AOR (95% CI) P value
Gender
 Female 323 152 1    
 Male 395 181 0.8 (0.6–1.1) 0.15
Age (month)
 > 15 627 291 1    
 ≤ 15 88 40 1.0 (0.6–1.5) 0.96
Duration of illness (day)
 ≤ 2 235 125 1    
 > 2 262 122 0.8 (0.5–1.1) 0.17
Enrolment body temperature (°C)
 < 38 389 159 1   1  
 ≥ 38 330 175 1.6 (1.2–2.2) 0.001 1.3 (1.0–1.8) 0.09
History of fever at enrolment
 Absent 109 26 1   1  
 Present 610 308 3.3 (2.0–5.2) < 0.0001 3.0 (1.8–4.9) <0.0001
Fever on day 1
 Absent 611 267 1   1  
 Present 91 58 2.3 (1.4–3.6) 0.001 1.8 (1.1–2.9) 0.02
Haematocrit (%)
 < 37 641 271 1   1  
 ≥ 37 78 63 5.7 (3.2–10.3) < 0.0001 5.5 (3.0–10.2) <0.0001
Parasitaemia (μL−1)
 ≤ 100,000 631 227 1   1  
 > 100,000 85 55 2.3 (1.5–3.8) < 0.0001 2.1 (1.3–3.5) 0.004
Parasitaemia on day 1
 Absent 288 133 1    
 Present 431 201 1.0 (0.8–1.4) 0.84
Gametocytaemia (D0)
 Present 31 7 1   1  
 Absent 688 327 3.1 (1.3–7.3) 0.01 1.7 (0.5–5.8) 0.36
Gametocyteamia (within D0–7)
 Present 61 16 1   1  
 Absent 658 318 2.6 (1.5–4.7) 0.001 1.4 (0.6–3.3) 0.44
Parasite clearance time (day)
 ≤ 2 563 259 1    
 > 2 155 75 1.1 (0.8–1.6) 0.66
Fever clearance time (day)
 ≤ 2 455 223 1    
 > 2 19 10 1.2 (0.5–2.9) 0.94
Season of enrolment
 Dry (November–March) 43 16 1    
 Wet (April–October) 676 318 1.5 (0.8–2.8) 0.27
Drug treatment
 DHP 251 120 1    
 AL 234 113 1.0 (0.7–1.5) 0.99
 AA 234 101 0.8 (0.6–1.2) 0.35   
  1. OR odd ratio; AOR adjusted odd ratio, CI confidence interval, DAFH drug-attributable fall in haematocrit, DHP dihydroartemisinin-piperaquine, AL artemether-lumefantrine, AA artesunate-amodiaquine